Pembrolizumab is an intravenously administered drug that is already approved for use in other types of cancers. It is now explored in a clinical trial as an initial (first line) treatment option for people diagnosed with advanced gastric or gastroesophageal adenocarcinomas. If licensed for use in the UK, pembrolizumab would provide a new treatment option for patients who currently have a poor life expectancy and few treatment options.
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line
Interventions:
Pembrolizumab (Keytruda; MK-3475)
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2017